---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-229101"
form_type: "8-K"
ticker: "QNCX"
cik: "0001662774"
company_name: "Quince Therapeutics, Inc."
filed_at: "2023-09-06T23:59:59+00:00"
generated_at: "2026-06-10T23:28:01.309724+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Appoints Charles S. Ryan as President; subsidiary issues up to $1M promissory note to EryDel S.p.A.

## Summary
- Promissory note of up to $1.0M to EryDel S.p.A. in two tranches: $500k at 5.07% per annum; second $500k at AFR.
- Maturity July 1, 2024; obligations discharged upon closing of Stock Purchase Agreement or termination in certain circumstances.
- Charles S. Ryan, Ph.D. appointed President, effective Sept 1, 2023; previously President/CEO of Travecta Therapeutics, CEO of Neurotrope.
- Compensation: $500k base salary, up to 40% bonus, option for 545,000 shares vesting over 4 years.
- Severance: 12-month salary on qualifying termination; 18-month salary if change of control, plus equity acceleration and health benefits.

## SEC filing metadata
- accession: 0001193125-23-229101
- form_type: 8-K
- ticker: QNCX
- cik: 0001662774
- company_name: Quince Therapeutics, Inc.
- filed_at: 2023-09-06T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 2.03, 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1662774/000119312523229101/0001193125-23-229101-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1662774/000119312523229101/d437171d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-229101
- JSON: https://secwatch.observer/filing/0001193125-23-229101.json
- Plain text: https://secwatch.observer/filing/0001193125-23-229101.txt

## Key facts
- Debt Financings
  Quince Therapeutics, Inc. incurred loan of up to $1.0 million with Erydel S.p.A. at 5.07% per annum maturing July 1, 2024.
  - Instrument: loan
  - Principal: up to $1.0 million
  - Counterparty: Erydel S.p.A.
  - Rate: 5.07% per annum
  - Maturity: July 1, 2024
  - Event: incurrence
  source text: shares (società per azioni) incorporated under the laws of Italy (“EryDel”) (the “Promissory Note”), pursuant to which EryDel Italy promised to make advances to EryDel of up to $1.0 million. The Company previously entered into a Stock Purchase Agreement, dated as of July 21, 2023, by and among the Company, EryDel, and the other parties thereto. Under the terms of
  evidence_url: https://www.sec.gov/Archives/edgar/data/1662774/000119312523229101/0001193125-23-229101-index.htm
- Executive change
  Charles S. Ryan was appointed as President at Quince Therapeutics, Inc..
  - Action: appointed
  - Role: President
  source text: On August 30, 2023, the Board of Directors of the Company approved the appointment of Charles S. Ryan, Ph.D., as the President of the Company, effective as of September 1, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1662774/000119312523229101/0001193125-23-229101-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.